nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2023-1S-58-64nnp-2080Research ArticleREVIEWSОБЗОРЫThe evolution of interferon therapy in multiple sclerosisЭволюция интерферонотерапии при рассеянном склерозеhttps://orcid.org/0000-0001-7153-5617БойкоО. В.BoykoO. V.

117997, Москва, ул. Островитянова, 1, стр. 10

1, Ostrovityanova St., Build. 10, Moscow 117997

https://orcid.org/0000-0002-2506-0371СмирноваН. Ф.SmirnovaN. F.

117997, Москва, ул. Островитянова, 1, стр. 10

117997, Москва, ул. Островитянова, 1

1, Ostrovityanova St., Build. 10, Moscow 117997

21, Ostrovityanova St., Moscow 117997

https://orcid.org/0000-0002-2975-4151БойкоА. Н.BoykoA. N.

Алексей Николаевич Бойко

117997, Москва, ул. Островитянова, 1, стр. 10

117997, Москва, ул. Островитянова, 1

Alexey Nikolaevich Boyko

1, Ostrovityanova St., Build. 10, Moscow 117997

21, Ostrovityanova St., Moscow 117997

boykoan13@gmail.comФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА РоссииРоссияFederal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of RussiaRussian FederationФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России; кафедра неврологии, нейрохирургии и медицинской генетики ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияFederal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia; Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian Federation202321082023150(Suppl. 1)5864Copyright © Boyko O.V., Smirnova N.F., Boyko A.N., 20232023Бойко О.В., Смирнова Н.Ф., Бойко А.Н.Boyko O.V., Smirnova N.F., Boyko A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2080

The article reviews the evolution of interferon-β (IFN-β) in the treatment of multiple sclerosis (MS) from the first high-dose interferons to the most recent pegylated forms. The results of pivotal trials are presented and discussed. The main problems of the first IFN-β were: 1) moderate efficacy in the presence of neutralizing antibodies (NAB, in 20% of treated patients), leading to a decrease in efficacy, 2) poor tolerability due to frequent injections (every other day), 3) severe local reactions and flu-like syndrome. Pegillation made it possible to extend the duration of administration to one injection every 14 days and to reduce the probability of NAB to less than 1% of all treated patients. The first drug administered subcutaneously had a pronounced flu-like syndrome; the domestic drug SamPEG-IFN-β1a administered intramuscularly was better tolerated with similar efficacy.

В статье приведен обзор эволюции интерферонов β (ИФНβ) в лечении рассеянного склероза (РС) от первых высокодозных интерферонов до новейших пегилированных форм. Приведены и обсуждаются результаты базовых исследований. Основными проблемами первых ИФНβ были: 1) умеренная эффективность при наличии нейтрализующих антител (НАТ; у 20% пролеченных), что приводило к снижению эффективности; 2) плохая переносимость из-за частых инъекций (через день); 3) выраженные местные реакции и гриппоподобный синдром. Пегилирование позволило уменьшить частоту введения до одной инъекции в 14 дней, снизило вероятность образования НАТ до менее 1% среди всех пролеченных. Нежелательным явлением терапии первым препаратом, вводимым подкожно, был выраженный гриппоподобный синдром; отечественный препарат самПЭГ-ИФН-β1а, применяемый внутримышечно, лучше переносится и имеет сходную эффективность.

рассеянный склерозлечениеинтерфероны βпегилированные интерфероны βmultiple sclerosistreatmentinterferons-βpegylated interferons-βСтатья спонсируется компанией «Биокад»This article has been supported by BiocadReferencesKappos L. Interferons in multiple sclerosis. Neurol Clin. 2005 Feb;23(1):189-214, vii-viii. doi: 10.1016/j.ncl.2004.10.004Kappos L. Interferons in multiple sclerosis. Neurol Clin. 2005 Feb;23(1):189-214, vii-viii. doi: 10.1016/j.ncl.2004.10.004Haji Abdolvahab M, Mofrad MR, Schellekens H. Interferon Beta: From Molecular Level to Therapeutic Effects. Int Rev Cell Mol Biol. 2016;326:343-72. doi: 10.1016/bs.ircmb.2016.06.001. Epub 2016 Jul 20.Haji Abdolvahab M, Mofrad MR, Schellekens H. Interferon Beta: From Molecular Level to Therapeutic Effects. Int Rev Cell Mol Biol. 2016;326:343-72. doi: 10.1016/bs.ircmb.2016.06.001. Epub 2016 Jul 20.Michalska A, Blaszczyk K, Wesoly J, Bluyssen HAR. A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)- Stimulated Gene Expression and Controls Type I and Type II IFN Responses. Front Immunol. 2018 May 28;9:1135. doi: 10.3389/fimmu.2018.01135Michalska A, Blaszczyk K, Wesoly J, Bluyssen HAR. A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)- Stimulated Gene Expression and Controls Type I and Type II IFN Responses. Front Immunol. 2018 May 28;9:1135. doi: 10.3389/fimmu.2018.01135Dumitrescu L, Constantinescu CS, Tanasescu R. Recent developments in interferon-based therapies for multiple sclerosis. Expert Opin Biol Ther. 2018 Jun;18(6):665-80. doi: 10.1080/14712598.2018.1462793. Epub 2018 Apr 20.Dumitrescu L, Constantinescu CS, Tanasescu R. Recent developments in interferon-based therapies for multiple sclerosis. Expert Opin Biol Ther. 2018 Jun;18(6):665-80. doi: 10.1080/14712598.2018.1462793. Epub 2018 Apr 20.De Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007 Jul 13;282(28):20053-7. doi: 10.1074/jbc.R700006200. Epub 2007 May 14.De Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem. 2007 Jul 13;282(28):20053-7. doi: 10.1074/jbc.R700006200. Epub 2007 May 14.Maimaitijiang G, Watanabe M, Shinoda K, et al. Long-term use of interferon-β in multiple sclerosis increases Vδ1–Vδ2–Vγ9–γδ T cells that are associated with a better outcome. J Neuroinflammation. 2019 Sep 13;16(1):179. doi: 10.1186/s12974-019-1574-5Maimaitijiang G, Watanabe M, Shinoda K, et al. Long-term use of interferon-β in multiple sclerosis increases Vδ1–Vδ2–Vγ9–γδ T cells that are associated with a better outcome. J Neuroinflammation. 2019 Sep 13;16(1):179. doi: 10.1186/s12974-019-1574-5Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304. Erratum in: Ann Neurol. 1996 Sep;40(3):480.Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 Mar;39(3):285-94. doi: 10.1002/ana.410390304. Erratum in: Ann Neurol. 1996 Sep;40(3):480.Paty DW, Boiko AN. Beta-interferons delay the switch from relapsing-remitting to secondary progressive multiple sclerosis. Neurology. 2000;54(Suppl. 3):A337. doi: 10.1212/wnl.54.3.337Paty DW, Boiko AN. Beta-interferons delay the switch from relapsing-remitting to secondary progressive multiple sclerosis. Neurology. 2000;54(Suppl. 3):A337. doi: 10.1212/wnl.54.3.337Brown JWL, Coles A, Horakova D, et al.; MSBase Study Group. Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019 Jan 15;321(2):175-87. doi: 10.1001/jama.2018.20588Brown JWL, Coles A, Horakova D, et al.; MSBase Study Group. Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019 Jan 15;321(2):175-87. doi: 10.1001/jama.2018.20588Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf. 2000 Feb;22(2):149-59. doi: 10.2165/00002018-200022020-00006Bayas A, Rieckmann P. Managing the adverse effects of interferon-beta therapy in multiple sclerosis. Drug Saf. 2000 Feb;22(2):149-59. doi: 10.2165/00002018-200022020-00006Reder AT, Feng X. How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res. 2014 Aug;34(8):589-99. doi: 10.1089/jir.2013.0158Reder AT, Feng X. How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res. 2014 Aug;34(8):589-99. doi: 10.1089/jir.2013.0158Newsome SD, Scott TF, Arnold DL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143. doi: 10.1177/1756286418791143Newsome SD, Scott TF, Arnold DL, et al. Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN. Ther Adv Neurol Disord. 2018 Aug 28;11:1756286418791143. doi: 10.1177/1756286418791143Interferon beta-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):655-61. doi: 10.1212/wnl.43.4.655Interferon beta-1b is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):655-61. doi: 10.1212/wnl.43.4.655Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999 Aug;46(2):197-206. doi: 10.1002/1531-8249(199908)46:2<197::aid-ana9>3.0.co;2-pLi DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol. 1999 Aug;46(2):197-206. doi: 10.1002/1531-8249(199908)46:2<197::aid-ana9>3.0.co;2-pMolyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000 Nov;123 (Pt 11):2256-63. doi: 10.1093/brain/123.11.2256Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000 Nov;123 (Pt 11):2256-63. doi: 10.1093/brain/123.11.2256Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 Nov 7;352(9139):1498-504. Erratum in: Lancet. 1999 Feb 20;353(9153):678.Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 Nov 7;352(9139):1498-504. Erratum in: Lancet. 1999 Feb 20;353(9153):678.PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferonbeta-1a in relapsing MS. Neurology. 2001 Jun 26;56(12):1628-36. doi: 10.1212/wnl.56.12.1628. Erratum in: Neurology. 2001 Sep 25;57(6):1146.PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferonbeta-1a in relapsing MS. Neurology. 2001 Jun 26;56(12):1628-36. doi: 10.1212/wnl.56.12.1628. Erratum in: Neurology. 2001 Sep 25;57(6):1146.Gold R, Rieckmann P, Chang P, Abdalla J; PRISMS Study Group. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol. 2005 Aug;12(8):649-56. doi: 10.1111/j.1468-1331.2005.01083.xGold R, Rieckmann P, Chang P, Abdalla J; PRISMS Study Group. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol. 2005 Aug;12(8):649-56. doi: 10.1111/j.1468-1331.2005.01083.xCohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1826. Dosage error in article text.Cohen BA, Rivera VM. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis. Curr Med Res Opin. 2010 Apr;26(4):827-38. doi: 10.1185/03007991003604018. Erratum in: Curr Med Res Opin. 2010 Aug;26(8):1826. Dosage error in article text.Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferonbeta-1a in secondary progressive MS: Clinical results. Neurology. 2001 Jun 12;56(11):1496-504. doi: 10.1212/wnl.56.11.1496Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferonbeta-1a in secondary progressive MS: Clinical results. Neurology. 2001 Jun 12;56(11):1496-504. doi: 10.1212/wnl.56.11.1496Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009 Jan;6(1):1-16. doi: 10.1517/17425240802650568Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv. 2009 Jan;6(1):1-16. doi: 10.1517/17425240802650568Baker DP, Lin EY, Lin K, et al. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem. 2006 Jan-Feb;17(1):179-88. doi: 10.1021/bc050237qBaker DP, Lin EY, Lin K, et al. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem. 2006 Jan-Feb;17(1):179-88. doi: 10.1021/bc050237qKang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009 Jun;14(2):363-80. doi: 10.1517/14728210902907847Kang JS, Deluca PP, Lee KC. Emerging PEGylated drugs. Expert Opin Emerg Drugs. 2009 Jun;14(2):363-80. doi: 10.1517/14728210902907847Calabresi PA, Kieseier BC, Arnold DL, et al.; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.Calabresi PA, Kieseier BC, Arnold DL, et al.; ADVANCE Study Investigators. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2015 Jul;21(8):1025-35. doi: 10.1177/1352458514557986. Epub 2014 Nov 28.Kieseier BC, Arnold DL, Balcer LJ, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler. 2015 Jul;21(8):1025-35. doi: 10.1177/1352458514557986. Epub 2014 Nov 28.Бойко АН, Бахтиярова КЗ, Дудин ВА и др. Новый пегилированный интерферон бета-1а (сампэгинтерферон бета-1а, BCD-054) в терапии ремиттирующего рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10-2):100-9. doi: 10.17116/jnevro201911910100Boyko AN, Bakhtiiarova KZ, Dudin VA, et al. The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(10-2):100-9. doi: 10.17116/jnevro201911910100 (In Russ.).Бойко АН, Бойко ОВ, Бахтиярова КЗ и др. Эффективность и безопасность сампегинтерферона β-1а в лечении ремиттирующего рассеянного склероза: данные 52 недель терапии в рамках рандомизированного, двойного слепого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162Boyko AN, Boyko OV, Bakhtiyarova KZ, et al. Efficacy and safety of sampeginterferon-β1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162 (In Russ.).Бойко АН. Пути повышения приверженности длительной инъекционной терапии при рассеянном склерозе на примере пегилированного интерферона-бета-1а (сампэгинтерферон-бета-1а). Неврология, нейропсихиатрия, психосоматика. 2022;14(S1):34-7. doi: 10.14412/2074-2711-2022-1S-34-37Boyko AN. Ways to improve adherence to longterm injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon-β1a) Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology Neuropsychiatry Psychosomatics. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162 (In Russ.).

The authors declare that there are no conflicts of interest present.